Laura Waite
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Laura Waite has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Albertino Damasceno
Faculty of Medicine, Eduardo Mondlane University , Maputo
1 shared publication - Alexander Chen
Centre for Cardiovascular Research, Torrens University Australia, 88 Wakefield Street , Adelaide, SA, 5000
1 shared publication - Ana Olga Mocumbi
Universidade Eduardo Mondlane, Campus Universitário, Maputo, Mozambique
1 shared publication - Angela L. Bingham
American College of Clinical Pharmacy Lenexa Kansas USA
1 shared publication - Benedicta Ngwenchi Nkeh-Chungag
Biological and Environmental Sciences Mthatha Eastern Cape 5099 Walter Sisulu University
1 shared publication - Brooklyn T. Cobb
Memorial Hermann Southwest Hospital
1 shared publication
Latest Publications
- Open Access
- 28 June 2024
- Published by International Society of Global Health in Journal of Global Health
- Vol. 14, 04136
Projected burden and distribution of elevated blood pressure levels and its consequence among adolescents in sub-Saharan Africa
Background There is minimal data on the number of adolescents in sub-Saharan Africa (SSA) with elevated blood pressure (BP) at increased risk of future cardiovascular events. Combining country -specific population data with data derived from two previously conducted meta -analyses (one African -specific, one based on international cohorts), we sought to address this knowledge deficit. Methods We used meta -analysis data from 37 926 adolescents participating in 36 contemporary SSA studies to generate sex -specific proportions of adolescents aged 10-14 and 15-19 years with elevated BP. The estimates were applied to the 2021 World Bank population data for each country in SSA. We then applied the rate of cardiovascular events attributable to elevated BP levels, derived from a meta -analysis of 17 observational, longitudinal cohort studies comprising 4.5 million young adults (non -African), to determine the excess number of cardiovascular events linked to hypertension among those aged 15-19 years transitioning to adulthood. Results The estimated prevalence of elevated BP among male and female adolescents aged 10-14 years living in SSA was 7.2% (95% confidence interval (CI) = 4.9-9.9) and 6.9% (95% CI = 4.7-9.5), respectively, which increased to 13.0% (95% CI = 10.6-15.6) and 12.5% (95% CI = 10.4-15.3) among male and female adolescents aged 15-19 years, respectively. Consequently, we estimate that 13.6/138.0 million (95% CI = 10.4-17.3) male and 12.9/135.7 million (95% CI = 9.83-16.3) female adolescents living in SSA have elevated BP. Among the estimated 16.1 million adolescents aged 15-19 years with elevated BP approaching adulthood, the projected excess in cardiovascular events attributable to hypertension (vs normotension) is 201 000 (95% CI = 115 000-322 000) to 503 000 (95% CI = 286 000-805 000) over the next 10-25 years. Conclusions Based on the best available data, we estimate that 26.5 million adolescents living in SSA have elevated BP. If left undetected and untreated among those approaching adulthood (those aged 15-19 years), they will experience >0.5 million excess cardiovascular events associated with persistently elevated BP within the next 25 years.
- 28 June 2024
- Published by International Society of Global Health in Journal of Global Health
- Vol. 14, 04136
Open AccessProjected burden and distribution of elevated blood pressure levels and its consequence among adolescents in sub-Saharan Africa
Background There is minimal data on the number of adolescents in sub-Saharan Africa (SSA) with elevated blood pressure (BP) at increased risk of future cardiovascular events. Combining country -specific population data with data derived from two previously conducted meta -analyses (one African -specific, one based on international cohorts), we sought to address this knowledge deficit. Methods We used meta -analysis data from 37 926 adolescents participating in 36 contemporary SSA studies to generate sex -specific proportions of adolescents aged 10-14 and 15-19 years with elevated BP. The estimates were applied to the 2021 World Bank population data for each country in SSA. We then applied the rate of cardiovascular events attributable to elevated BP levels, derived from a meta -analysis of 17 observational, longitudinal cohort studies comprising 4.5 million young adults (non -African), to determine the excess number of cardiovascular events linked to hypertension among those aged 15-19 years transitioning to adulthood. Results The estimated prevalence of elevated BP among male and female adolescents aged 10-14 years living in SSA was 7.2% (95% confidence interval (CI) = 4.9-9.9) and 6.9% (95% CI = 4.7-9.5), respectively, which increased to 13.0% (95% CI = 10.6-15.6) and 12.5% (95% CI = 10.4-15.3) among male and female adolescents aged 15-19 years, respectively. Consequently, we estimate that 13.6/138.0 million (95% CI = 10.4-17.3) male and 12.9/135.7 million (95% CI = 9.83-16.3) female adolescents living in SSA have elevated BP. Among the estimated 16.1 million adolescents aged 15-19 years with elevated BP approaching adulthood, the projected excess in cardiovascular events attributable to hypertension (vs normotension) is 201 000 (95% CI = 115 000-322 000) to 503 000 (95% CI = 286 000-805 000) over the next 10-25 years. Conclusions Based on the best available data, we estimate that 26.5 million adolescents living in SSA have elevated BP. If left undetected and untreated among those approaching adulthood (those aged 15-19 years), they will experience >0.5 million excess cardiovascular events associated with persistently elevated BP within the next 25 years.
- Open Access
- 14 November 2023
- Published by University of Minnesota in INNOVATIONS in pharmacy
- Vol. 14 (4) , 11
Student Pharmacist-Led Basic Life Support Training for High School Students Improves Knowledge and Skill Achievement
Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, and review articles that focus on the leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. INNOVATIONS in pharmacy is an academic, peer reviewed, open-access journal. Sponsored by U of MN College of Pharmacy Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy. A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, review articles, and student projects that focus on leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. INNOVATIONS in pharmacy.
- 14 November 2023
- Published by University of Minnesota in INNOVATIONS in pharmacy
- Vol. 14 (4) , 11
Open AccessStudent Pharmacist-Led Basic Life Support Training for High School Students Improves Knowledge and Skill Achievement
Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, and review articles that focus on the leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. INNOVATIONS in pharmacy is an academic, peer reviewed, open-access journal. Sponsored by U of MN College of Pharmacy Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy. A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, review articles, and student projects that focus on leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. INNOVATIONS in pharmacy.
- 26 March 2018
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 52 (9) , 884-897
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Where Are We Now?
Objective: To synthesize the literature and provide guidance to practitioners regarding double therapy (DT) and triple therapy (TT) in patients with atrial fibrillation (AF) requiring percutaneous coronary intervention (PCI). Data Sources: PubMed and MEDLINE (January 2000 to February 2018) were searched using the following terms: atrial fibrillation, myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, anticoagulation, dual-antiplatelet therapy, clopidogrel, aspirin, ticagrelor, prasugrel, and triple therapy. Study Selection and Data Extraction: The results included randomized and nonrandomized clinical trials and meta-analyses. Each study was reported based on study design, population, intervention, comparator, and key cardiovascular (CV) and bleeding outcomes. Data Synthesis: A total of 15 studies were included in the review. The majority of studies evaluating DT and TT utilized clopidogrel and warfarin as components of the regimen, although there are emerging data with newer agents. Evidence purporting DT regimens to be equally effective in preventing CV events and improved safety profiles compared with TT regimens included populations with relatively low risk for recurrent CV events, and many of these studies were observational in nature. Overall, current evidence as well as American and European guidelines support the use of TT in patients with AF who require PCI for the least possible amount of time, depending on patient-specific factors involving bleeding and thrombosis. Conclusions: In the majority of patients with AF who require PCI, TT should be used for the shortest period of time possible. DT regimens may be used in patients requiring PCI who have low risk for thrombosis and/or high bleeding risk.
- 26 March 2018
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 52 (9) , 884-897
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Where Are We Now?
Objective: To synthesize the literature and provide guidance to practitioners regarding double therapy (DT) and triple therapy (TT) in patients with atrial fibrillation (AF) requiring percutaneous coronary intervention (PCI). Data Sources: PubMed and MEDLINE (January 2000 to February 2018) were searched using the following terms: atrial fibrillation, myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, anticoagulation, dual-antiplatelet therapy, clopidogrel, aspirin, ticagrelor, prasugrel, and triple therapy. Study Selection and Data Extraction: The results included randomized and nonrandomized clinical trials and meta-analyses. Each study was reported based on study design, population, intervention, comparator, and key cardiovascular (CV) and bleeding outcomes. Data Synthesis: A total of 15 studies were included in the review. The majority of studies evaluating DT and TT utilized clopidogrel and warfarin as components of the regimen, although there are emerging data with newer agents. Evidence purporting DT regimens to be equally effective in preventing CV events and improved safety profiles compared with TT regimens included populations with relatively low risk for recurrent CV events, and many of these studies were observational in nature. Overall, current evidence as well as American and European guidelines support the use of TT in patients with AF who require PCI for the least possible amount of time, depending on patient-specific factors involving bleeding and thrombosis. Conclusions: In the majority of patients with AF who require PCI, TT should be used for the shortest period of time possible. DT regimens may be used in patients requiring PCI who have low risk for thrombosis and/or high bleeding risk.